Vislink Technologies, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Vislink Technologies, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $38.29M | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $47.82M | Apr 1, 2019 |
| FY2013 | Dec 31, 2013 | $406.0K | Mar 6, 2014 |
| FY2013 | Dec 31, 2012 | $0 | Mar 6, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $27.73M | May 2, 2025 |
| FY2024 | Dec 31, 2023 | $27.48M | May 2, 2025 |
| FY2023 | Dec 31, 2022 | $28.13M | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | $33.88M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $22.88M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $28.94M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $38.29M | Apr 1, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $47.82M | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $6.57M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $932.0K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $628.0K | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | $406.0K | Mar 31, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($20.50M) | May 2, 2025 |
| FY2024 | Dec 31, 2023 | ($9.13M) | May 2, 2025 |
| FY2023 | Dec 31, 2022 | ($13.54M) | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | ($16.39M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($17.58M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($18.05M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($14.87M) | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | ($10.35M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($20.90M) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($17.86M) | Mar 31, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($21.51M) | May 2, 2025 |
| FY2024 | Dec 31, 2023 | ($10.60M) | May 2, 2025 |
| FY2023 | Dec 31, 2022 | ($14.07M) | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | ($17.75M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($17.89M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($17.20M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($14.43M) | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | ($23.39M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($22.86M) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($19.86M) | Mar 31, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $4.56M | May 2, 2025 |
| FY2024 | Dec 31, 2023 | $3.49M | May 2, 2025 |
| FY2023 | Dec 31, 2022 | $4.06M | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | $3.05M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.70M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $3.23M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $7.87M | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | $9.80M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $6.11M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $4.93M | Mar 31, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($6.84M) | May 2, 2025 |
| FY2024 | Dec 31, 2023 | ($9.75M) | May 2, 2025 |
| FY2023 | Dec 31, 2022 | ($9.42M) | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | ($9.60M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($14.35M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($8.36M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($6.38M) | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | ($4.49M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($8.08M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $519.0K | May 2, 2025 |
| FY2024 | Dec 31, 2023 | $698.0K | May 2, 2025 |
| FY2023 | Dec 31, 2022 | $466.0K | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | $201.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $258.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $401.0K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $69.0K | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | $374.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $12.0K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $34.0K | Mar 31, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $26.18M | May 2, 2025 |
| FY2024 | Dec 31, 2023 | $44.99M | May 2, 2025 |
| FY2023 | Dec 31, 2022 | $51.80M | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | $68.12M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $20.65M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $23.60M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $28.81M | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | $36.65M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $19.90M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $16.57M | Mar 31, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $8.97M | May 2, 2025 |
| FY2024 | Dec 31, 2023 | $8.02M | May 2, 2025 |
| FY2023 | Dec 31, 2022 | $8.14M | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | $11.49M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $10.65M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $14.38M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $18.52M | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | $20.15M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $7.26M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $6.28M | Mar 31, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $17.21M | May 2, 2025 |
| FY2024 | Dec 31, 2023 | $36.98M | May 2, 2025 |
| FY2024 | Dec 31, 2022 | $43.65M | May 2, 2025 |
| FY2023 | Dec 31, 2021 | $56.63M | Apr 3, 2024 |
| FY2022 | Dec 31, 2020 | $10.00M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $9.23M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $10.29M | Apr 15, 2021 |
| FY2019 | Dec 31, 2017 | $16.50M | Apr 1, 2020 |
| FY2018 | Dec 31, 2016 | $12.64M | Apr 1, 2019 |
| FY2017 | Dec 31, 2015 | $10.29M | Apr 2, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $0 | Mar 31, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($329.73M) | May 2, 2025 |
| FY2024 | Dec 31, 2023 | ($309.23M) | May 2, 2025 |
| FY2023 | Dec 31, 2022 | ($300.10M) | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | ($286.54M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($270.15M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($252.57M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($234.53M) | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | ($219.65M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($209.30M) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($188.40M) | Mar 31, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $5.50M | May 2, 2025 |
| FY2024 | Dec 31, 2023 | $8.48M | May 2, 2025 |
| FY2023 | Dec 31, 2022 | $25.63M | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | $36.23M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.19M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.74M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $2.01M | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | $2.80M | Apr 1, 2019 |
| FY2018 | Dec 31, 2016 | $9.05M | Apr 1, 2019 |
| FY2017 | Dec 31, 2015 | $368.0K | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (8) | May 2, 2025 |
| FY2024 | Dec 31, 2023 | (3) | May 2, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (8) | May 2, 2025 |
| FY2024 | Dec 31, 2023 | (3) | May 2, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Apr 3, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 2.47M | May 2, 2025 |
| FY2024 | Dec 31, 2023 | 2.44M | May 2, 2025 |
| FY2023 | Dec 31, 2022 | 2.37M | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | 45.82M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 21.38M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 3.59M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | 1.88M | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | 14.90M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 7.61M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | 168,563 | Mar 31, 2017 |